Posted by Michael Wonder on 13 Aug 2016
TGA approves Tagrisso (osimertinib mesylate)
12 August 2016 - The TGA has approved AstraZeneca's Tagrisso (osimertinib mesylate).
Tagrisso was registered by TGA on 3 August 2016 for for the treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer based on tumour response rate and duration of response.
